VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 15 filers reported holding VERONA PHARMA PLC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $51,329,501 | -11.6% | 3,549,758 | -1.7% | 4.74% | +3.9% |
Q1 2024 | $58,087,748 | -31.2% | 3,610,177 | -15.1% | 4.56% | -34.0% |
Q4 2023 | $84,488,370 | +22.0% | 4,249,918 | 0.0% | 6.92% | -8.8% |
Q3 2023 | $69,273,663 | -22.9% | 4,249,918 | 0.0% | 7.59% | +22.4% |
Q2 2023 | $89,843,267 | +5.3% | 4,249,918 | 0.0% | 6.20% | +4.7% |
Q1 2023 | $85,338,353 | +2346294.1% | 4,249,918 | 0.0% | 5.92% | +1313.4% |
Q4 2022 | $3,637 | -100.0% | 4,249,918 | 0.0% | 0.42% | -91.3% |
Q3 2022 | $43,434,000 | +277.0% | 4,249,918 | +54.5% | 4.80% | +314.4% |
Q2 2022 | $11,522,000 | -16.0% | 2,749,918 | 0.0% | 1.16% | +22.4% |
Q1 2022 | $13,722,000 | -25.7% | 2,749,918 | 0.0% | 0.94% | -15.2% |
Q4 2021 | $18,479,000 | +22.6% | 2,749,918 | 0.0% | 1.11% | +64.5% |
Q3 2021 | $15,070,000 | -24.4% | 2,749,918 | -9.8% | 0.68% | -21.6% |
Q2 2021 | $19,937,000 | -21.8% | 3,048,507 | 0.0% | 0.86% | -3.7% |
Q1 2021 | $25,486,000 | +19.4% | 3,048,507 | 0.0% | 0.90% | -5.9% |
Q4 2020 | $21,340,000 | +12.2% | 3,048,507 | 0.0% | 0.95% | -13.4% |
Q3 2020 | $19,023,000 | +172.3% | 3,048,507 | +104.2% | 1.10% | +119.4% |
Q2 2020 | $6,987,000 | +13.6% | 1,492,951 | 0.0% | 0.50% | -10.1% |
Q1 2020 | $6,151,000 | -19.2% | 1,492,951 | 0.0% | 0.56% | -22.0% |
Q2 2019 | $7,614,000 | -21.5% | 1,492,951 | 0.0% | 0.71% | -26.2% |
Q1 2019 | $9,704,000 | -27.8% | 1,492,951 | 0.0% | 0.97% | -43.6% |
Q4 2018 | $13,437,000 | -28.1% | 1,492,951 | 0.0% | 1.72% | -8.8% |
Q3 2018 | $18,677,000 | +568.9% | 1,492,951 | 0.0% | 1.88% | +422.8% |
Q2 2018 | $2,792,000 | -90.6% | 1,492,951 | 0.0% | 0.36% | -91.5% |
Q1 2018 | $29,859,000 | +68.5% | 1,492,951 | 0.0% | 4.23% | +11.4% |
Q4 2017 | $17,723,000 | -22.7% | 1,492,951 | 0.0% | 3.80% | -18.0% |
Q3 2017 | $22,917,000 | +179.2% | 1,492,951 | +112.0% | 4.63% | +124.0% |
Q2 2017 | $8,208,000 | – | 704,225 | – | 2.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Octagon Capital Advisors LP | 2,369,000 | $47,095,720 | 7.54% |
NEA Management Company, LLC | 5,108,563 | $111,024,890 | 7.40% |
Vivo Capital, LLC | 4,249,918 | $84,488,370 | 6.92% |
Aisling Capital Management LP | 1,115,352 | $22,173,198 | 6.61% |
Rosalind Advisors, Inc. | 250,000 | $4,970,000 | 4.09% |
First Turn Management, LLC | 1,206,291 | $23,981,065 | 3.44% |
Knoll Capital Management, LLC | 200,000 | $3,976,000 | 3.29% |
Frazier Life Sciences Management, L.P. | 3,014,349 | $59,925,258 | 3.20% |
Tri Locum Partners LP | 293,112 | $5,827,067 | 2.66% |
Carlyle Group Inc. | 2,457,500 | $48,805,950 | 2.35% |